Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo for adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer post-neoadjuvant chemoradiotherapy. This positive opinion follows Phase 3 CheckMate -577 trial results, which showed that Opdivo improved disease-free survival compared to placebo. The European Commission will now review the recommendation.
Bristol Myers Squibb (NYSE: BMY) announced that the CHMP has recommended Conditional Marketing Authorization for Abecma (idecabtagene vicleucel), a CAR T cell therapy for relapsed and refractory multiple myeloma. This recommendation follows positive outcomes from the Phase 2 KarMMa study involving 128 patients. The European Commission will review this recommendation, with a decision expected within 67 days. Abecma targets patients with limited options, marking a potential advancement in their treatment. The therapy has previously been granted access to the EMA's PRIME scheme.
Bristol Myers Squibb (NYSE: BMY) received full Marketing Authorization from the European Commission for Onureg (azacitidine tablets) as a maintenance therapy for adults with acute myeloid leukemia (AML) in complete remission. Onureg becomes the first once-daily oral maintenance therapy to showcase significant survival benefits across various AML subtypes. The approval follows the QUAZAR AML-001 Phase 3 clinical trial, which reported a median overall survival of 24.7 months for patients on Onureg compared to 14.8 months on placebo. The treatment aims to address the unmet needs for AML patients not eligible for stem cell transplantation.
Bristol-Myers Squibb (NYSE: BMY) and Eisai Co., Ltd. have announced a collaboration for the co-development and commercialization of MORAb-202, an antibody drug conjugate targeting advanced solid tumors. Eisai will conduct studies in Japan and the U.S., moving toward registrational stages next year. Bristol-Myers Squibb will invest $650 million, including $200 million for R&D, and up to $2.45 billion in potential milestones. Both companies will share profits and costs in specified territories, with Bristol-Myers Squibb handling regions outside these areas.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.49 per share on its common stock, payable on August 2, 2021, with a record date of July 2, 2021. Additionally, a $0.50 dividend on its convertible preferred stock will be paid on September 1, 2021, to stockholders on record by August 10, 2021. The company continues its commitment to returning value to its shareholders.
Bristol Myers Squibb (BMY) and Acceleron Pharma (XLRN) presented promising results from the Phase 2 BEYOND study on Reblozyl® (luspatercept-aamt) for adult patients with non-transfusion dependent beta thalassemia at the EHA 2021 Virtual Congress. 77.7% of patients treated with Reblozyl showed a hemoglobin increase of ≥1.0 g/dL, compared to 0% in the placebo group. The study highlights Reblozyl's potential in improving the quality of life for patients, addressing a significant unmet medical need. The study involved 145 patients over a 48-week treatment period, showing higher efficacy than placebo.
Bristol Myers Squibb (NYSE: BMY) and GRYT Health launched the 'Advocacy Exchange', enhancing the existing COVID Advocacy Exchange to better support patient advocacy organizations. This virtual platform is designed to foster collaboration among advocacy organizations, patients, and industry leaders, providing 24/7 access to educational resources and a searchable resource library. The initiative aims to address health disparities and improve patient experiences through ongoing dialogue and the sharing of best practices.
Bristol Myers Squibb (NYSE:BMY) will release its second quarter 2021 financial results on July 28, 2021, at 8 a.m. ET. Executives will discuss the results during a conference call open to investors and the public. Interested parties can access the live webcast at investor.bms.com or by dialing 888-204-4368 (U.S.) and +1 313-209-4906 (international) using confirmation code 1720109. A replay will be available from 11:30 a.m. ET on July 28 until 11:30 a.m. ET on August 11, 2021.
Bristol Myers Squibb (NYSE: BMY) announced promising topline results from the TRANSFORM Phase 3 study, evaluating Breyanzi (lisocabtagene maraleucel) as a second-line treatment for adults with relapsed or refractory large B-cell lymphoma (LBCL). The trial achieved its primary endpoint, showing significant improvement in event-free survival compared to standard salvage therapy followed by high-dose chemotherapy. Safety outcomes were consistent with previous data, revealing no new concerns. This marks a pivotal moment as Breyanzi demonstrates potential to replace aggressive treatment regimens, impacting the treatment landscape for LBCL.
Bristol Myers Squibb (NYSE: BMY) is set to participate in the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, scheduled for June 10, 2021, at 9:40 a.m. ET. Key executives, including Chris Boerner, Ph.D., and Samit Hirawat, M.D., will engage in a fireside chat discussing the company's strategic initiatives. A live webcast will be available for investors and the public at investor.bms.com, with an archived version accessible later that day.